Outdoor Artificial Light at Night Tied to New Exudative AMD
By Lori Solomon HealthDay Reporter
THURSDAY, Jan. 18, 2024 -- Higher levels of residential outdoor artificial light at night (OALAN) are associated with an increased risk for incident exudative age-related macular degeneration (EAMD), according to a study published online Jan. 16 in JAMA Network Open.
Su Hwan Kim, Ph.D., from Seoul National University Hospital in South Korea, and colleagues examined the association between exposure to OALAN and the risk for incident EAMD. The analysis included 4,078 individuals (aged 50 years and older) with newly diagnosed EAMD (2010 through 2011) and matched controls (1:30).
The researchers found that in fully adjusted models, an interquartile range (IRQ; 55.8 nW/cm2/sr) increase in OALAN level was associated with a higher risk for incident EAMD (hazard ratio [HR], 1.67; 95 percent confidence interval [CI], 1.56 to 1.78). The exposure-response curve showed a nonlinear, concave upward slope, which became more pronounced at higher levels of light exposure (at approximately 110 nW/cm2/sr). In urban areas, an interquartile range increase in OALAN was associated with an increased risk for incident EAMD (HR, 1.46; 95 percent CI, 1.33 to 1.61), but this finding was not seen in rural areas (HR, 1.01; 95 percent CI, 0.84 to 1.22).
"Further studies incorporating comprehensive information on exposure, individual adaptive behaviors, and potential mediators are recommended to deepen our understanding in this area," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.